BCMA-GPRC5D CAR-T Cells is under clinical development by Guangzhou Bio-gene Technology and currently in Phase II for Refractory Multiple Myeloma. According to GlobalData, Phase II drugs for Refractory Multiple Myeloma have a 35% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BCMA-GPRC5D CAR-T Cells’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BCMA-GPRC5D CAR-T Cells overview
The therapeutic candidate is under development for the treatment of relapsed and refractory multiple myeloma. It comprises of T-cells genetically engineered to express chimeric antigen receptors (CAR) targeting BCMA expressing cells and GPRC5D expressing cells. It is administered parenterally.
For a complete picture of BCMA-GPRC5D CAR-T Cells’s drug-specific PTSR and LoA scores, buy the report here.